Positive results for ATX-MS-1467 trial in relapsing MS

[MSUK]

Apitope announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing multiple sclerosis treated by intradermal injection of ATX-MS-1467. The same effect was not seen in the subcutaneously dosed group. These encouraging results will now need confirmation in appropriate Phase II trials....... Read More - http://www.ms-uk.org/index.cfm/ATXMS1467